Key Clinical Research
Huntington's Disease
KINECT-HD
120 Participants
A randomized, double-blind, placebo-controlled phase 3 multi-center clinical trial using uHDRS Total Maximal Chorea (TMC) score to evaluate the safety and tolerability of valbenazine for participants with HD.
FDA Approval August 2023
FIRST-HD
90 Participants
A randomized, double blind, placebo controlled study of SD-809 extended release for the treatment of chorea associated with Huntington’s disease.
FDA Approval April 2017
TETRA-HD
72 Participants
A randomized, double-blind, placebo-controlled, study of tetrabenazine for the treatment of Huntington’s chorea.
FDA Approval August 2008
Parkinson's Disease
PPMI
1,700 Participants
The Parkinson’s Progression Markers Initiative is a global, longitudinal observational study seeking markers of progression in Parkinson’s disease.
DATATOP
800 Participants
A 2 x 2 factorial, double-blind, placebo-controlled, phase III multi-center clinical trial in participants with early Parkinson’s disease to assess the efficacy of tocopherol and deprenyl.
NILO-PD
75 Participants
A randomized, double-blind, placebo-controlled, phase III, study to define the safety, tolerability, clinical and exploratory biological activity of the chronic administration of Nilotinib in participants with Parkinson's disease.
STEADY-PD3
336 Participants
A Phase III double-blind placebo-controlled parallel group study of isradipine as a disease modifying agent in participants with early Parkinson’s disease.
NET-PD LS1
1,720 Participants
Multi-center, double-blind, parallel group, placebo-controlled study of creatine in subjects with stably treated Parkinson’s disease.
Other Neurological Disorders
HYPHOP
42 Participants
A randomized, controlled study of acetazolamide vs. dichlorphenamide vs. placebo in individuals with hyperkalemic and hypokalemic periodic paralysis.
FDA Approval August 2015
FACOMS
1,000+ Participants
Friedreich’s Ataxia Clinical Outcome Measure Study. (Supported the development of FDA-Approved drug
Omaveloxolone for Friedreich’s Ataxia).
CCM LONGITUDINAL
400+ Participants
A 12-month large scale, international, online longitudinal natural history study in Cerebral Cavernous Malformations.
PRISM FM
1,044+ Participants
An international cross-sectional study to ascertain the symptoms and symptomatic themes most important to individuals with fibromyalgia.
PRISM ALS
497 Participants
A cross-sectional study to ascertain the symptoms and symptomatic themes most important to adults with amyotrophic lateral sclerosis.
PRISM DMD
113 Caregiver Participants, 87 Adult & Minor Participants
A cross-sectional study to ascertain the symptoms and symptomatic themes most important to adults and minors with duchenne muscular dystrophy and caregivers of individuals with duchenne muscular dystrophy.
We have conducted additional clinical trials for other conditions, including dental caries, epilepsy, HIV, influenza, intracranial hypertension, stroke, and testicular cancer.